ClinicalTrials.gg
Drug

Adagrasib clinical trials

Also written MRTX849, Krazati, BMS-986503 and KRAS G12C Inhibitor MRTX849.

studies test it
28
open now
8
in phase 3
4
first study started
2019

How each study uses adagrasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the adagrasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
12 Dec 2022 · KRAZATI · NDA 216340 (FDA, Drugs@FDA)
European Union
5 Jan 2024 · Krazati · EMEA/H/C/006013 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Adagrasib
24

Brand

Krazati
7

Development codes

MRTX849
18
BMS-986503
3

Other names

KRAS G12C Inhibitor MRTX849
2

Studies by the year they started

28 studies that test it; most in 2023 (8)

Studies that test adagrasib, by start year
YearStudies
20192
20202
20213
20222
20238
20244
20252
20265

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
15
Phase 2
12
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 16 · Other 12

Mirati Therapeutics Inc. (14) · M.D. Anderson Cancer Center (6) · Alliance for Clinical Trials in Oncology (1) · ETOP IBCSG Partners Foundation (1) · Roswell Park Cancer Institute (1) · City of Hope Medical Center (1) · Ryan Gentzler, MD (1) · Bristol-Myers Squibb (1)

Often tested with

Tested in the same studies.

Bevacizumab (2) · Durvalumab (2) · Cetuximab (2) · Abemaciclib (1) · Entrectinib (1) · Batoprotafib (1) · Eltrombopag (1) · CIMAvax EGF (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Adagrasib is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 3

Studies that test adagrasib.

Studies

Open first, then newest update. How each study uses adagrasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 28

See all 28 studies that test adagrasib →

Given beside what is tested · 6 — adagrasib is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with adagrasib

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call adagrasib · ClinicalTrials.gg INT001658

  • MeSH (NLM) C000718190adagrasibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 8EOO6HQF8YADAGRASIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q105816120adagrasibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C157493AdagrasibOne source FDA
  • DrugBank DB15568One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.